Analgesic and toxic effects of ABT-594 resemble epibatidine and nicotine in rats-Reference-Cited by-同舟云学术

Analgesic and toxic effects of ABT-594 resemble epibatidine and nicotine in rats

Published:2000-04 Issue:3 Volume:85 Page:443-450
ISSN:0304-3959
Container-title:Pain
language:en
Short-container-title:

Author:

Boyce S.,Webb J. K.,Shepheard S. L.,Russell M. G.N.,Hill R. G.,Rupniak N. M.J.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Anesthesiology and Pain Medicine,Neurology (clinical),Neurology

Reference22 articles.

1. ABT-594 (R)-5-(2-azetidinylmethoxy)-2-chloropyridine: a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II. In vivo characterization.;Bannon;J Pharmacol Exp Ther,1998

2. Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors.;Bannon;Science,1998

3. Role of the nucleus raphe magnus in antinociception produced by ABT-594: immediate early gene responses possibly linked to neuronal nicotinic acetylcholine receptors on serotonergic neurons.;Bitner;J Neurosci,1998

4. Frog venom cocktail yields a one-handed painkiller.;Bradley;Science,1993

5. Antinociceptive effects of the novel neuronal nicotinic acetylcholine receptor agonist, ABT-594, in mice.;Decker;Eur J Pharmacol,1998

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, docking, synthesis, and characterization of novel N'(2-phenoxyacetyl) nicotinohydrazide and N'(2-phenoxyacetyl)isonicotinohydrazide derivatives as anti-inflammatory and analgesic agents;Journal of Molecular Structure;2022-01

2. Behavioral and Molecular Basis of Cholinergic Modulation of Pain: Focus on Nicotinic Acetylcholine Receptors;Behavioral Pharmacology of the Cholinergic System;2020

3. The nicotinic modulation of pain;Pakistan Journal of Pharmaceutical Sciences;2020-01-01

4. Acute Administration of Desformylflustrabromine Relieves Chemically Induced Pain in CD-1 Mice;Molecules;2019-03-07

5. Green tobacco sickness: mecamylamine, varenicline, and nicotine vaccine as clinical research tools and potential therapeutics;Expert Review of Clinical Pharmacology;2019-01-24